USPTO serial 77377366
THERABANK
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- PINO, BRIAN
- Law office
- TMO LAW OFFICE 114 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with THERABANK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Denmark Hill, London, GB
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Consulting and advisory services relating to diagnostic preparations and products, namely, prediction of response of individuals to pharmaceutical products and treatments for diseases and disorders of the central nervous system and psychiatric diseases and disorders; Consulting and advisory services relating to diagnostic preparations and products, namely, development, testing and efficacy of pharmaceutical preparations and products for the treatment of diseases and disorders of the central nervous system and psychiatric diseases and disorders; Consulting and advisory services relating to diagnostic preparations and products, namely, provision of goods containing reagents for use in the collection and testing of DNA, RNA and bodily tissues; Consulting and advisory services relating to diagnostic apparatus and diagnostic instruments, namely, prediction of response of individuals to pharmaceutical products and treatments for diseases and disorders of the central nervous system and psychiatric diseases and disorders; Consulting and advisory services relating to diagnostic apparatus and diagnostic instruments namely, development, testing and efficacy, of apparatus and diagnostic instruments for the treatment of diseases and disorders of the central nervous system and psychiatric diseases and disorders; Consulting and advisory services relating to diagnostic apparatus and diagnostic instruments, namely, provision of assays or assay kits for use in the collection and testing of DNA, RNA and bodily tissues; Design and control of pharmacogenetic diagnostic tests for prediction of response of individuals to pharmaceutical products and treatments for disorders of the central nervous system and psychiatric diseases and disorders; Design and control of pharmacogenetic diagnostic tests for disorders and diseases of the central nervous system and psychiatric diseases and disorders; Design and control of pharmacogenetic tests, including the devising, compiling and testing of algorithms and mathematical systems for predicting response to a pharmaceutical product based on individual genetic profile; Scientific research related to pharmacogenetics; Research and advisory services relating to pharmaceuticals | ACTIVE | — |
| 044 | Medical diagnostic services; Medical diagnostic testing relating to the human body, namely, analysis of samples to predict response of individuals to pharmaceutical products and treatments for disorders of the central nervous system and psychiatric diseases and disorders; Medical diagnostic testing relating to the human body, namely, analysis of samples to confirm diagnosis of diseases and disorders of the central nervous system and psychiatric diseases and disorders; Medical clinical services, namely, analysis of samples of DNA, RNA and bodily tissues to prescribe the prescribe the most efficient and/or efficacious pharmaceutical product to the patient; Medical clinical services, namely, the taking of samples of bodily tissues for analysis in connection with the prescription of pharmaceuticals or other medical treatment; Medical and scientific research in the nature of conducting clinical trials; Compilation of medical reports relating to prediction of response of individuals to pharmaceutical products and treatments for disorders of the central nervous system and psychiatric diseases and disorders; Compilation of medical reports relating to confirmation of diagnosis of diseases and disorders of the body, and prescription of most efficient and efficacious pharmaceutical product or method for treatment thereof; Compilation of medical reports as a resource of phenotypic and genotypic data relating to diseases and disorders of the central nervous system and psychiatric diseases and disorders; Conducting medical examinations for diagnosis and treatments of disease; Testing and profiling of pharmaceutical preparations and treatments for medical purposes; Computer aided diagnostic testing services relating to the human body | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 4, 2010 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 4, 2010 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 1, 2009 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jun 1, 2009 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jun 1, 2009 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jun 1, 2009 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 28, 2009 | ALIE | ASSIGNED TO LIE | — |
| Nov 28, 2008 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 28, 2008 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 28, 2008 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Nov 18, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 18, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 18, 2008 | ALIE | ASSIGNED TO LIE | — |
| Nov 5, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 5, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 5, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 5, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 29, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 26, 2008 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Jan 25, 2008 | NWAP | NEW APPLICATION ENTERED | — |